Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 7481597, 14 pages
https://doi.org/10.1155/2017/7481597
Research Article

Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors

1Division of Endocrinology and Metabolism, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
2Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
3Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Correspondence should be addressed to Kulkanya Chokephaibulkit; ht.ca.lodiham@ohc.aynakluk

Received 31 October 2016; Accepted 29 December 2016; Published 15 February 2017

Academic Editor: Marcelo A. Soares

Copyright © 2017 Jeerunda Santiprabhob et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. C. Quinn, “HIV epidemiology and the effects of antiviral therapy on long-term consequences,” AIDS, vol. 22, supplement 3, pp. S7–S12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Chokephaibulkit, A. Kariminia, P. Oberdorfer et al., “Characterizing HIV manifestations and treatment outcomes of perinatally infected adolescents in asia,” The Pediatric Infectious Disease Journal, vol. 33, no. 3, pp. 291–294, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Anuurad, A. Bremer, and L. Berglund, “HIV protease inhibitors and obesity,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 17, no. 5, pp. 478–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Lake and J. S. Currier, “Metabolic disease in HIV infection,” The Lancet Infectious Diseases, vol. 13, no. 11, pp. 964–975, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Fortuny, Á. Deyà-Martínez, E. Chiappini, L. Galli, M. de Martino, and A. Noguera-Julian, “Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents,” The Pediatric Infectious Disease Journal, vol. 34, no. 5, supplement 1, pp. S36–S43, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Barlow-Mosha, A. R. Eckard, G. A. McComsey, and P. M. Musoke, “Metabolic complications and treatment of perinatally HIV-infected children and adolescents,” Journal of the International AIDS Society, vol. 16, Article ID 18600, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Blázquez, J. T. Ramos-Amador, T. Saínz et al., “Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults,” BMC Infectious Diseases, vol. 15, no. 1, article 119, 2015. View at Publisher · View at Google Scholar
  8. M. E. Geffner, K. Patel, T. L. Miller et al., “Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study,” Hormone Research in Paediatrics, vol. 76, no. 6, pp. 386–391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. P. Dubé and J. J. Cadden, “Lipid metabolism in treated HIV infection,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 25, no. 3, pp. 429–442, 2011. View at Publisher · View at Google Scholar
  10. K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation,” Diabetic Medicine, vol. 23, no. 5, pp. 469–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Grundy, “Metabolic syndrome update,” Trends in Cardiovascular Medicine, vol. 26, no. 4, pp. 364–373, 2016. View at Publisher · View at Google Scholar
  12. G. M. Aldrovandi, J. C. Lindsey, D. L. Jacobson et al., “Morphologic and metabolic abnormalities in vertically HIV-infected children and youth,” AIDS, vol. 23, no. 6, pp. 661–672, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. L. Miller, E. J. Orav, S. E. Lipshultz et al., “Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1,” Journal of Pediatrics, vol. 153, no. 4, pp. 491–497, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Innes, K. L. Abdullah, R. Haubrich, M. F. Cotton, and S. H. Browne, “High prevalence of dyslipidemia and insulin resistance in HIV-infected prepubertal African children on antiretroviral therapy,” The Pediatric Infectious Disease Journal, vol. 35, no. 1, pp. e1–e7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. L. C. dos Reis, P. H. de Carvalho Rondo, H. H. de Sousa Marques, and S. B. de Andrade, “Dyslipidaemia and insulin resistance in vertically HIV-infected children and adolescents,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 105, no. 4, pp. 197–203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. V. A. Triant, H. Lee, C. Hadigan, and S. K. Grinspoon, “Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 7, pp. 2506–2512, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. G. Hemkens and H. C. Bucher, “HIV infection and cardiovascular disease,” European Heart Journal, vol. 35, no. 21, pp. 1373–1381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Hazra, L. F. Hance, J. P. Monteiro et al., “Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected latin American children,” The Pediatric Infectious Disease Journal, vol. 32, no. 7, pp. 757–759, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Arpadi, S. Shiau, R. Strehlau et al., “Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy,” Archives of Disease in Childhood, vol. 98, no. 4, pp. 258–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. Center for Disease Control and Prevention, “1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM,” MMWR Recommendations and Reports, vol. 43, no. 12, pp. 1–19, 1994. View at Google Scholar
  21. Nutrition Division, Department of Health, Ministry of Public Health, National growth references for children under 20 years of age, Thailand, 1999.
  22. European Paediatric Lipodystrophy Group, “Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe,” AIDS, vol. 18, no. 10, pp. 1443–1451, 2004. View at Publisher · View at Google Scholar
  23. K. A. Lichtenstein, D. J. Ward, A. C. Moorman et al., “Clinical assessment of HIV-associated lipodystrophy in an ambulatory population,” AIDS, vol. 15, no. 11, pp. 1389–1398, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Zimmet, G. Alberti, F. Kaufman et al., “The metabolic syndrome in children and adolescents,” The Lancet, vol. 369, no. 9579, pp. 2059–2061, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. H. D. McCarthy and M. Ashwell, “A study of central fatness using waist-to-height ratios in UK children and adolescents over two decades supports the simple message—“keep your waist circumference to less than half your height”,” International Journal of Obesity, vol. 30, no. 6, pp. 988–992, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. D. S. Freedman, H. S. Kahn, Z. Mei et al., “Relation of body mass index and waist-to-height ratio to cardiovascular disease risk factors in children and adolescents: the Bogalusa Heart Study,” The American Journal of Clinical Nutrition, vol. 86, no. 1, pp. 33–40, 2007. View at Google Scholar · View at Scopus
  27. American Diabetes Association, “Standards of medical care in diabetes—2008,” Diabetes Care, vol. 31, supplement 1, pp. S12–S54, 2008. View at Google Scholar
  28. G. Valerio, M. R. Licenziati, A. Iannuzzi et al., “Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 16, no. 4, pp. 279–284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, “Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002. View at Google Scholar
  30. D. A. D. S. Group, N. Friis-Moller, P. Reiss et al., “Class of antiretroviral drugs and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 356, no. 17, pp. 1723–1735, 2007. View at Publisher · View at Google Scholar
  31. J. Jantarapakde, N. Phanuphak, C. Chaturawit et al., “Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected thai adults,” AIDS Patient Care and STDs, vol. 28, no. 7, pp. 331–340, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. S. W. Worm and J. D. Lundgren, “The metabolic syndrome in HIV,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 25, no. 3, pp. 479–486, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. P. R. Alencastro, S. C. Fuchs, F. H. Wolff, M. L. Ikeda, A. B. M. Brandão, and N. T. Barcellos, “Independent predictors of metabolic syndrome in HIV-infected patients,” AIDS Patient Care and STDs, vol. 25, no. 11, pp. 627–634, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Biron, C. Bobin-Dubigeon, C. Volteau et al., “Metabolic syndrome in french HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy,” AIDS Research and Human Retroviruses, vol. 28, no. 12, pp. 1672–1678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Samaras, H. Wand, M. Law, S. Emery, D. Cooper, and A. Carr, “Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia,” Diabetes Care, vol. 30, no. 1, pp. 113–119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Gazzaruso, P. Sacchi, A. Garzaniti, P. Fratino, R. Bruno, and G. Filice, “Prevalence of metabolic syndrome among HIV patients,” Diabetes Care, vol. 25, no. 7, pp. 1253–1254, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Falasca, C. Ucciferri, L. Manzoli et al., “Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy,” International Journal of Immunopathology and Pharmacology, vol. 20, no. 3, pp. 519–527, 2007. View at Google Scholar · View at Scopus
  38. S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr., and C. Lenfant, “Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition,” Circulation, vol. 109, no. 3, pp. 433–438, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Aekplakorn, V. Chongsuvivatwong, P. Tatsanavivat, and P. Suriyawongpaisal, “Prevalence of metabolic syndrome defined by the international diabetes federation and national cholesterol education program criteria among thai adults,” Asia-Pacific Journal of Public Health, vol. 23, no. 5, pp. 792–800, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Beltrán-Sánchez, M. O. Harhay, M. M. Harhay, and S. McElligott, “Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010,” Journal of the American College of Cardiology, vol. 62, no. 8, pp. 697–703, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Jericó, H. Knobel, M. Montero et al., “Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors,” Diabetes Care, vol. 28, no. 1, pp. 132–137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. D. L. Jacobson, A. M. Tang, D. Spiegelman et al., “Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey),” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 4, pp. 458–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. E. Sobieszczyk, D. R. Hoover, K. Anastos et al., “Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study,” Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 3, pp. 272–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. K. D. Miller, E. Jones, J. A. Yanovski, R. Shankar, I. Feuerstein, and J. Falloon, “Visceral abdominal-fat accumulation associated with use of indinavir,” Lancet, vol. 351, no. 9106, pp. 871–875, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Lichtenstein, A. Balasubramanyam, R. Sekhar, and E. Freedland, “HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms,” AIDS Research and Therapy, vol. 4, article 14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Dimock, V. Thomas, A. Cushing et al., “Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood,” Metabolism, vol. 60, no. 6, pp. 874–880, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. A. L. Rosenbloom, J. H. Silverstein, S. Amemiya, P. Zeitler, and G. J. Klingensmith, “Type 2 diabetes in children and adolescents,” Pediatric Diabetes, vol. 10, supplement 12, pp. 17–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. J. Karter, D. Schillinger, A. S. Adams et al., “Elevated rates of diabetes in Pacific Islanders and Asian subgroups: the Diabetes Study of Northern California (DISTANCE),” Diabetes Care, vol. 36, no. 3, pp. 574–579, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. T. L. Alderete, C. M. Toledo-Corral, and M. I. Goran, “Metabolic basis of ethnic differences in diabetes risk in overweight and obese youth,” Current Diabetes Reports, vol. 14, no. 2, article 455, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Srivanich, C. Ngarmukos, and S. Sungkanuparph, “Prevalence of and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand,” Journal of the International Association of Physicians in AIDS Care, vol. 9, no. 6, pp. 358–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. W. Aekplakorn, V. Kosulwat, and P. Suriyawongpaisal, “Obesity indices and cardiovascular risk factors in Thai adults,” International Journal of Obesity, vol. 30, no. 12, pp. 1782–1790, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. I. J. Paik and D. P. Kotler, “The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 25, no. 3, pp. 469–478, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Kalra and N. Agrawal, “Diabetes and HIV: current understanding and future perspectives,” Current Diabetes Reports, vol. 13, no. 3, pp. 419–427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. E. R. Feeney and P. W. G. Mallon, “Insulin resistance in treated HIV infection,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 25, no. 3, pp. 443–458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Murata, P. W. Hruz, and M. Mueckler, “The mechanism of insulin resistance caused by HIV protease inhibitor therapy,” The Journal of Biological Chemistry, vol. 275, no. 27, pp. 20251–20254, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. R. C. Hresko and P. W. Hruz, “HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4,” PLoS ONE, vol. 6, no. 9, Article ID e25237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. T. T. Brown, X. Li, S. R. Cole et al., “Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study,” AIDS, vol. 19, no. 13, pp. 1375–1383, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. S. De Wit, C. A. Sabin, R. Weber et al., “Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study,” Diabetes Care, vol. 31, no. 6, pp. 1224–1229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. M. A. Noor, J. C. Lo, K. Mulligan et al., “Metabolic effects of indinavir in healthy HIV-seronegative men,” AIDS, vol. 15, no. 7, pp. F11–F18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Rosso, A. Parodi, G. d'Annunzio et al., “Evaluation of insulin resistance in a cohort of HIV-infected youth,” European Journal of Endocrinology, vol. 157, no. 5, pp. 655–659, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. P. A. Randell, A. G. Jackson, L. Zhong, K. Yale, and G. J. Moyle, “The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers,” Antiviral Therapy, vol. 15, no. 2, pp. 227–233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Bitnun, E. Sochett, P. Babyn et al., “Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children,” AIDS, vol. 17, no. 9, pp. 1319–1327, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. P. E. Sax and P. Kumar, “Tolerability and safety of HIV protease inhibitors in adults,” Journal of Acquired Immune Deficiency Syndromes, vol. 37, no. 1, pp. 1111–1124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. T. T. Brown and M. J. Glesby, “Management of the metabolic effects of HIV and HIV drugs,” Nature Reviews Endocrinology, vol. 8, no. 1, pp. 11–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. J. E. Gallant, S. Staszewski, A. L. Pozniak et al., “Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial,” JAMA, vol. 292, no. 2, pp. 191–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Van Leth, P. Phanuphak, K. Ruxrungtham et al., “Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study,” Lancet, vol. 363, no. 9417, pp. 1253–1263, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Tungsiripat, D. Kitch, M. J. Glesby et al., “A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206,” AIDS, vol. 24, no. 11, pp. 1781–1784, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Mauss, J. Stechel, R. Willers, G. Schmutz, F. Berger, and W. O. Richter, “Differentiating hyperlipidaemia associated with antiretroviral therapy,” AIDS, vol. 17, no. 2, pp. 189–194, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. S. W. Worm, C. Sabin, R. Weber et al., “Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study,” Journal of Infectious Diseases, vol. 201, no. 3, pp. 318–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Anastos, D. Lu, Q. Shi et al., “Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens,” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 1, pp. 34–42, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. Guidelines for the use of antiretrovirus agents in pediatric HIV infection, 2016, http://aidsinfo.nih.gov/guidelines.